Literature DB >> 2114940

Skeletal muscle wasting and protein-energy malnutrition in children with a newly diagnosed acute leukemia.

E K Koskelo1, U M Saarinen, M A Siimes.   

Abstract

The changes in skeletal muscle mass of 14 children with newly diagnosed acute leukemia were studied during the first 24 weeks of antileukemia therapy. A muscle index was calculated from the femoral quadriceps muscle thickness, measured by using an ultrasound method, and from the body surface area. Serum albumin concentration was used as a biochemical indicator of protein status. Some children had muscle wasting before diagnosis. The highest degree of muscle wasting developed by 4 to 6 weeks with an average of 27% decrease of the muscle index. Because of simultaneous increase of adipose tissue (average, 33% at 6 weeks and 37% at 12 weeks), the relative body weight or the limb circumferences did not decrease. Muscle mass recovery occurred within the next 6 months. Our data emphasize that changes in the relative body weight or limb circumferences do not reveal nutritional protein depletion and muscle wasting that occurs in children with newly diagnosed acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114940     DOI: 10.1002/1097-0142(19900715)66:2<373::aid-cncr2820660229>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.

Authors:  Laura A A Gilliam; Daniel S Lark; Lauren R Reese; Maria J Torres; Terence E Ryan; Chien-Te Lin; Brook L Cathey; P Darrell Neufer
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-06-21       Impact factor: 4.310

2.  Risk factors for osteoporosis in long-term survivors of intracranial germ cell tumors.

Authors:  M J Kang; S M Kim; Y A Lee; C H Shin; S W Yang; J S Lim
Journal:  Osteoporos Int       Date:  2011-11-05       Impact factor: 4.507

3.  Skeletal Muscle and Childhood Cancer: Where are we now and where we go from here.

Authors:  Chelsea G Goodenough; Robyn E Partin; Kirsten K Ness
Journal:  Aging Cancer       Date:  2021-05-20

4.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

5.  Protein and lipid metabolism in nephrotic infants on peritoneal dialysis after nephrectomy.

Authors:  M Antikainen
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

6.  Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapy.

Authors:  Thomas Chaillou; Ashley McPeek; Johanna T Lanner
Journal:  Physiol Rep       Date:  2017-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.